Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab

Humoral and cell-mediated immune responses are blunted after SARS-CoV-2 vaccination in patients with a history of CD20 B-cell-depleting treatment.1 However, vaccination induces SARS-CoV-2-specific antibodies in patients treated with rituximab once peripheral B cells at least partially repopulate.2 Moreover, SARS-CoV-2-specific T cells, which have been found in 58% of patients who have had two…

Read the full article here

Related Articles